Phase III Clinical Trial of "Botulax®" to Treat Children With Cerebral Palsy

Inclusion criteria

• Children patients ages from 2years old to 10years old.
• Patients who diagnosed with cerebral palsy.
• Patients who diagnosed as Gross Motor Function Classification System level I, II, or III
• Patients who diagnosed as dynamic equinus foot deformity
• Patients who agree with participation and signed to written agreement by substitute. (Get a signature from children patients if possible)deformity and I, II or III level of Gross Motor Function Classification System

Exclusion criteria

• Patients who had previous injection of other botulinum toxin products in 3 months
• Patients with hypersensitivity history to botulinum toxin products previously
• Patients with neuromuscular junction disorder (myasthenia gravis, Lambert- Eaton syndrome, or amyotrophic lateral sclerosis, etc.)
• Those who have severe cardiovascular, kidney, liver, or respiratory diseases
• Those who are taking anticoagulant drugs or have bleeding disorder.
• Pratients with treatment of following drugs: Anticonvulsants, tranquilizers, narcotics, aminoglycoside antibiotics, muscle relaxtants like baclofen, blockers of parasympathetic nervous system, and levodopa.
• Patients who had history of surgery, plan to have surgery on legs, foot, or ankle.
• Patients who have evidence of fixed contractures regarding to Investigator
• Patients who have difference between two legs over 5cm
• Patients with severe athetoid movement
• Patients who had other treatments related to dynamic equinus foot deformity, such as alcohol injection or muscle relaxants
• Those who were not enrolled in other studies within 30 days, or were not paseed over 5 times of half life for clinical trial drugs.
• Patients who have possibility to take prevented drugs
• Subjects who are not eligible for this study based on investigator's judgement